# Semaglutide Research: The Mechanism and the Major Clinical Trials > Semaglutide research in depth: the central appetite mechanism, STEP, SUSTAIN-6, SELECT and FLOW outcomes, semaglutide weight loss, and how it compares with tirzepatide. The mechanism first, then the trial record — weight, cardiovascular events, kidney outcomes — each finding cited to its source. ## Before the details Semaglutide research splits cleanly into two halves: *how* it works and *what* it does. The how is mostly a brain story — the drug reaches the appetite-control regions and turns hunger down. The what is a trial story — large randomized studies measuring weight, blood sugar, heart attacks, strokes and kidney decline. This page leads with the mechanism, because the appetite circuitry explains the rest, then walks through the major trials in plain terms. Each number below is tied to a published study. The short version: large and consistent weight loss, fewer cardiovascular events in at-risk groups, and slower kidney decline in diabetes with kidney disease — set against a real side-effect burden covered on the [effects page](/effects). ## The mechanism: a central appetite drug Semaglutide activates the GLP-1 receptor, copying a gut hormone that signals fullness. By switching that receptor on, it boosts glucose-dependent insulin release from the pancreas, suppresses the counter-hormone glucagon when it is inappropriately high, and slows stomach emptying [5]. The glucose effects matter most in diabetes; the weight effect is largely separate, and largely central. In rodents, semaglutide reached the brain directly — through the brainstem area postrema and the hypothalamic arcuate nucleus, regions where the blood-brain barrier is leaky — and lowered body weight by cutting food intake and altering food preference, without reducing energy expenditure [4]. In other words it works on the *input* side of the energy balance, not the output side. Within the arcuate nucleus, GLP-1 receptor activation modulates the opposing POMC/CART (satiety) and NPY/AgRP (hunger) neuron populations in a way that depends on metabolic state and timing [8], and the arcuate nucleus itself is required for this class of drug to produce weight loss [9]. ## Semaglutide weight loss: the STEP program The defining weight result is STEP 1. In 1,961 adults with overweight or obesity and no diabetes, once-weekly subcutaneous semaglutide 2.4 mg produced a mean body-weight change of -14.9% from baseline to week 68, versus -2.4% with placebo — a treatment difference of about 12.4 percentage points [1]. The companion STEP 2 trial reported substantial weight reduction in adults who also had type 2 diabetes [10]. Beyond the scale, semaglutide improved a broad set of cardiometabolic markers — waist circumference, blood pressure, lipids, glycemia and inflammatory markers — in adults with overweight or obesity [14]. The weight effect is real and large; it is also not permanent without continued treatment, a point the [effects page](/effects) covers under weight regain. ## Cardiovascular and kidney outcomes Two cardiovascular trials anchor the heart story. SUSTAIN-6, in 3,297 people with type 2 diabetes at high cardiovascular risk, found once-weekly semaglutide (0.5 or 1.0 mg) reduced the composite of cardiovascular death, nonfatal heart attack or nonfatal stroke with a hazard ratio of 0.74 — while also flagging more diabetic-retinopathy complications (hazard ratio 1.76) in those with pre-existing eye disease [2]. SELECT then tested the question in obesity without diabetes: across 17,604 adults with established cardiovascular disease, semaglutide 2.4 mg cut those same events by 20% (hazard ratio 0.80) [3]. The kidneys benefited too. In FLOW, 3,533 people with type 2 diabetes and chronic kidney disease saw a 24% lower risk of major kidney events — kidney failure, a large drop in filtration, or kidney or cardiovascular death — on semaglutide 1.0 mg (hazard ratio 0.76) [6]. Together these trials moved semaglutide from a glucose-and-weight drug to one with documented organ-protective outcomes. ## Semaglutide vs tirzepatide The most direct comparison is SURMOUNT-5, a head-to-head trial in 751 adults with obesity. Over 72 weeks, tirzepatide produced greater mean weight loss than semaglutide — -20.2% versus -13.7%, a difference of roughly 6.5 percentage points that was statistically significant [7]. Tirzepatide is a different molecule: it engages two receptors (GIP and GLP-1) rather than semaglutide's one. That single trial says tirzepatide won on weight in this comparison; it does not collapse the two drugs into a ranking across every outcome. Semaglutide carries the larger cardiovascular and kidney outcome record (SELECT, FLOW), and the choice between agents in practice rests on the full clinical picture, not one endpoint. Both are GLP-1 receptor-active medicines, and both are named here only by their generic names. ## Oral semaglutide and the broader record Semaglutide also exists as a daily tablet. A meta-analysis of once-daily oral semaglutide reported reductions in HbA1c (a three-month blood-sugar average) and body weight, with a cardiovascular profile consistent with the GLP-1 receptor agonist class in type 2 diabetes [11]. Higher oral doses studied in the PIONEER PLUS trial (25 mg and 50 mg) improved blood sugar and weight further versus the 14 mg dose in inadequately controlled diabetes [13]. Against another injectable in the class, SUSTAIN 7 found semaglutide produced greater HbA1c and weight reductions than dulaglutide [12]. A 2024 mechanism review synthesizes the GLP-1 receptor-mediated metabolic and central actions and is candid that much of the fine-grained mechanistic detail comes from rodent work [15] — a useful reminder that the human outcome trials and the animal mechanism studies are answering different questions. --- A calm reading room for the semaglutide literature — the brain's appetite circuitry, the STEP, SUSTAIN, SELECT and FLOW readouts, and the honest open questions, cited from the published record and prescribed by no one.